Background and aims: Bromocriptine is a dopaminergic (D2) agonist that has shown hypoglycemic and normotensive activity in preclinical and clinical studies. The main objective of this study was to investigate the effect of bromocriptine plus metformin on glycaemia and blood pressure in patients with type 2 diabetes mellitus (T2DM).
Material and methods: An open-label randomised controlled trial was conducted for three months. It involved two groups (n=10), each containing 2 women and 8 men with an average age of 50 years. One group was given monotherapy (MT) with metformin (850 mg every 12 h) and the other combined therapy (CT) with the same dose of metformin plus an increasing dose of bromocriptine (from 1.25 mg per day to 2.5 mg per day). The parameters monitored were glycaemia, glycated hemoglobin (HbA1c), serum creatinine, blood pressure, and the body mass index.
Results: CT was able to significantly decrease the level of glycaemia, HbA1c and diastolic blood pressure, whereas MT had no effect on any of the measured variables.
Conclusions: The ability of CT with bromocriptine and metformin to control glycaemia and produce a normotensive effect reaffirms its advantages for controlling T2DM. Further research is needed to improve this therapeutic strategy.
1. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 36: 11-66, 2013.
2. International Diabetes Federation. International Diabetes Federation. 7th. Brussels, Belgium: 2015. IDF diabetes atlas; pp 1-144. Accessed at: http://www.diabetesatlas.org.
3. Villalpando S, de la Cruz V, Rojas R et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Publica Mex 52: 19-26, 2010.
4. Glamočlija U, Jevrić-Čaušević A. Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics. Acta Pharm 60: 387-406, 2010.
5. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities. Diabetes Metab Syndr 6: 54-8, 2012.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 40: 81-90, 2017.
7. Yang X, Xu Z, Zhang C, Cai Z, Zhang J. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochim Biophys Acta 1863: 1984-1990, 2017.
8. Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol 41: 197–8, 2009.
9. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23: 1154–1161, 2000.
10. Liang W, Gao L, Li N, et al. Efficacy and safety of Bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis. Horm Metab Res 47: 805-812, 2015.
11. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc 1: e002279, 2012.
12. Chamarthi B, Gaziano JM, Blonde L, et al. Timed bromocriptine-qr therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res 2015: 157698, 2015.
13. Chamarthi B, Cincotta AH. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin. Postgrad Med 129: 446-455, 2017.
14. Krysiak R, Okrzesik J, Okopien B. Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities. Exp Clin Endocrinol Diabetes 123: 561-6, 2015.
15. Shani M, Taylor TR, Vinker S, et al. Characteristics of diabetics with poor glycemic control who achieve good control. J Am Board Fam Med 21: 490-6, 2008.
16. Eckel RH, Jakicic JM, Ard JD, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63: 2960-84, 2014.
18. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1: 1265-1268, 1976.
19. Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial. Indian J Pharmacol 46: 24-28, 2014.
20. Krysiak R, Okrzesik J, Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 49: 242-249, 2015.
21. Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgrad Med 128: 761-769, 2016.
22. Arnold P, Scheurer D, Dake AW, et al. Hospital Guidelines for Diabetes Management and the Joint Commission-American Diabetes Association Inpatient Diabetes Certification. Am J Med Sci 351: 333-341, 2016.
23. Burgmaier M, Hellmich M, Marx N, Reith S. A score to quantify coronary plaque vulnerability in high-risk patients with type 2 diabetes: an optical coherence tomography study. Cardiovasc Diabetol 13:117, 2014.
24. Edsfeldt A, Gonçalves I, Grufman H, et al. Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. Arterioscler Thromb Vasc Biol 34: 2143-50, 2014.
25. Lynch CP, Strom Williams J, Voronca D, Walker RJ, Egede LE. Meaning of Illness and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Diabetes Educ 42: 220-227, 2016.
26. Rissling MB, Gray KE, Ulmer CS et al. Sleep Disturbance, Diabetes, and Cardiovascular Disease in Postmenopausal Veteran Women. Gerontologist 56: 54-66, 2016.
27. Lahlou S, Duarte GP. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Fundam Clin Pharmacol 12: 599-606, 1998.
28. Wacker J, Stemmler G. Agentic extraversion modulates the cardiovascular effects of the dopamine D2 agonist bromocriptine. Psychophysiology 43: 372-81, 2006.
29. Van Loon GR, Sole MJ, Bain J, Ruse JL. Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425-34, 1979.
30. Ensinger H, Majewski H, Hedler L, Starke K. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits. J Pharmacol Exp Ther 234: 681-90, 1985.
31. Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Prim Care Diabetes 10: 60-5, 2016.
32. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 52: 239-57, 2001.
33. Chatterjee PK. Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol 160: 1889-91, 2010.
34. Bahler L, Verberne HJ, Brakema E, et al. Bromocriptine and insulin sensitivity in lean and obese subjects. Endocr Connect 5: 44-52, 2016.
35. Gale JE, Cox HI, Qian J, Block GD, Colwell CS, Matveyenko AV. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms 26: 423-33, 2011.
36. Sridhar GR, Sanjana NSN. Sleep, circadian dysrhythmia, obesity and diabetes. World J Diabetes 7: 515-522, 2016.
37. Rakshit K, Thomas AP, Matveyenko AV. Does disruption of circadian rhythms contribute to beta-cell failure in type 2 diabetes? Curr Diab Rep 14: 474, 2014.
38. Bernsmeier C, Weisskopf DM, Pflueger MO, et al. Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls. PLoS One 10: e0143293, 2015.
39. Tan E, Scott EM. Circadian rhythms, insulin action, and glucose homeostasis. Curr Opin Clin Nutr Metab Care 17: 343-8, 2014.
40. Shi SQ, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol 23: 372-81, 2013.
41. Suzuki H. [Bromocriptine improves circadian rhythm in Rett syndrome]. No To Hattatsu 23:213-4, 1991.
42. Kok P, Roelfsema F, Frölich M, van Pelt J, Meinders AE, Pijl H. Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women. J Clin Endocrinol Metab 93: 3455-61, 2008.
43. Scranton R, Cincotta A. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 11: 269-79, 2010.